Cargando…

Overcoming cisplatin resistance by targeting the MTDH-PTEN interaction in ovarian cancer with sera derived from rats exposed to Guizhi Fuling wan extract

BACKGROUND: The well-known traditional Chinese herbal formula Guizhi Fuling Wan (GFW) was recently reported to improve the curative effects of chemotherapy for ovarian cancer with few clinical side effects. The present study aimed to investigate the reversal mechanism of sera derived from rats expos...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Li, Cao, Xueyun, Chen, Zhong, Guo, Xiaojuan, Yang, Lei, Zhou, Yubing, Bian, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076886/
https://www.ncbi.nlm.nih.gov/pubmed/32066429
http://dx.doi.org/10.1186/s12906-020-2825-9
_version_ 1783507308944293888
author Han, Li
Cao, Xueyun
Chen, Zhong
Guo, Xiaojuan
Yang, Lei
Zhou, Yubing
Bian, Hua
author_facet Han, Li
Cao, Xueyun
Chen, Zhong
Guo, Xiaojuan
Yang, Lei
Zhou, Yubing
Bian, Hua
author_sort Han, Li
collection PubMed
description BACKGROUND: The well-known traditional Chinese herbal formula Guizhi Fuling Wan (GFW) was recently reported to improve the curative effects of chemotherapy for ovarian cancer with few clinical side effects. The present study aimed to investigate the reversal mechanism of sera derived from rats exposed to Guizhi Fuling Wan extract (GFWE) in cisplatin-resistant human ovarian cancer SKOV3/DDP cells; the proteins examined included phosphatase and tensin homolog (PTEN) and metadherin (MTDH), and the possible protein interaction between PTEN and MTDH was explored. METHODS: GFWE was administered to healthy Wistar rats, and the sera were collected after five days. The PubMed and CNKI databases were searched for literature on the bioactive blood components in the sera. The systemsDock website was used to predict potential PTEN/MTDH interactions with the compounds. RT-qPCR, western blotting, and immunofluorescence analyses were used to analyze the mRNA and protein levels of MTDH and PTEN. Laser confocal microscopy and coimmunoprecipitation (co-IP) were used to analyze the colocalization and interaction between MTDH and PTEN. RESULTS: Sixteen bioactive compounds were identified in GFWE sera after searching the PubMed and CNKI databases. The systemsDock website predicted the potential PTEN/MTDH interactions with the compounds. RT-qPCR, western blotting, and immunofluorescence analyses showed decreased MTDH expression and increased PTEN expression in the sera. Laser confocal microscopy images and coimmunoprecipitation (co-IP) analyses demonstrated that a colocalization and interaction occurred between MTDH and PTEN, and the addition of the sera changed the interaction status. CONCLUSIONS: GFWE restored sensitivity to cisplatin by inhibiting MTDH expression, inducing PTEN expression, and improving the interaction between MTDH and PTEN in SKOV3/DDP cells, and these proteins and their interaction may serve as potential targets for cancer treatment. The sera may represent a new source of anticancer compounds that could help to manage chemoresistance more efficiently and safely.
format Online
Article
Text
id pubmed-7076886
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70768862020-03-19 Overcoming cisplatin resistance by targeting the MTDH-PTEN interaction in ovarian cancer with sera derived from rats exposed to Guizhi Fuling wan extract Han, Li Cao, Xueyun Chen, Zhong Guo, Xiaojuan Yang, Lei Zhou, Yubing Bian, Hua BMC Complement Med Ther Research Article BACKGROUND: The well-known traditional Chinese herbal formula Guizhi Fuling Wan (GFW) was recently reported to improve the curative effects of chemotherapy for ovarian cancer with few clinical side effects. The present study aimed to investigate the reversal mechanism of sera derived from rats exposed to Guizhi Fuling Wan extract (GFWE) in cisplatin-resistant human ovarian cancer SKOV3/DDP cells; the proteins examined included phosphatase and tensin homolog (PTEN) and metadherin (MTDH), and the possible protein interaction between PTEN and MTDH was explored. METHODS: GFWE was administered to healthy Wistar rats, and the sera were collected after five days. The PubMed and CNKI databases were searched for literature on the bioactive blood components in the sera. The systemsDock website was used to predict potential PTEN/MTDH interactions with the compounds. RT-qPCR, western blotting, and immunofluorescence analyses were used to analyze the mRNA and protein levels of MTDH and PTEN. Laser confocal microscopy and coimmunoprecipitation (co-IP) were used to analyze the colocalization and interaction between MTDH and PTEN. RESULTS: Sixteen bioactive compounds were identified in GFWE sera after searching the PubMed and CNKI databases. The systemsDock website predicted the potential PTEN/MTDH interactions with the compounds. RT-qPCR, western blotting, and immunofluorescence analyses showed decreased MTDH expression and increased PTEN expression in the sera. Laser confocal microscopy images and coimmunoprecipitation (co-IP) analyses demonstrated that a colocalization and interaction occurred between MTDH and PTEN, and the addition of the sera changed the interaction status. CONCLUSIONS: GFWE restored sensitivity to cisplatin by inhibiting MTDH expression, inducing PTEN expression, and improving the interaction between MTDH and PTEN in SKOV3/DDP cells, and these proteins and their interaction may serve as potential targets for cancer treatment. The sera may represent a new source of anticancer compounds that could help to manage chemoresistance more efficiently and safely. BioMed Central 2020-02-17 /pmc/articles/PMC7076886/ /pubmed/32066429 http://dx.doi.org/10.1186/s12906-020-2825-9 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Han, Li
Cao, Xueyun
Chen, Zhong
Guo, Xiaojuan
Yang, Lei
Zhou, Yubing
Bian, Hua
Overcoming cisplatin resistance by targeting the MTDH-PTEN interaction in ovarian cancer with sera derived from rats exposed to Guizhi Fuling wan extract
title Overcoming cisplatin resistance by targeting the MTDH-PTEN interaction in ovarian cancer with sera derived from rats exposed to Guizhi Fuling wan extract
title_full Overcoming cisplatin resistance by targeting the MTDH-PTEN interaction in ovarian cancer with sera derived from rats exposed to Guizhi Fuling wan extract
title_fullStr Overcoming cisplatin resistance by targeting the MTDH-PTEN interaction in ovarian cancer with sera derived from rats exposed to Guizhi Fuling wan extract
title_full_unstemmed Overcoming cisplatin resistance by targeting the MTDH-PTEN interaction in ovarian cancer with sera derived from rats exposed to Guizhi Fuling wan extract
title_short Overcoming cisplatin resistance by targeting the MTDH-PTEN interaction in ovarian cancer with sera derived from rats exposed to Guizhi Fuling wan extract
title_sort overcoming cisplatin resistance by targeting the mtdh-pten interaction in ovarian cancer with sera derived from rats exposed to guizhi fuling wan extract
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076886/
https://www.ncbi.nlm.nih.gov/pubmed/32066429
http://dx.doi.org/10.1186/s12906-020-2825-9
work_keys_str_mv AT hanli overcomingcisplatinresistancebytargetingthemtdhpteninteractioninovariancancerwithseraderivedfromratsexposedtoguizhifulingwanextract
AT caoxueyun overcomingcisplatinresistancebytargetingthemtdhpteninteractioninovariancancerwithseraderivedfromratsexposedtoguizhifulingwanextract
AT chenzhong overcomingcisplatinresistancebytargetingthemtdhpteninteractioninovariancancerwithseraderivedfromratsexposedtoguizhifulingwanextract
AT guoxiaojuan overcomingcisplatinresistancebytargetingthemtdhpteninteractioninovariancancerwithseraderivedfromratsexposedtoguizhifulingwanextract
AT yanglei overcomingcisplatinresistancebytargetingthemtdhpteninteractioninovariancancerwithseraderivedfromratsexposedtoguizhifulingwanextract
AT zhouyubing overcomingcisplatinresistancebytargetingthemtdhpteninteractioninovariancancerwithseraderivedfromratsexposedtoguizhifulingwanextract
AT bianhua overcomingcisplatinresistancebytargetingthemtdhpteninteractioninovariancancerwithseraderivedfromratsexposedtoguizhifulingwanextract